There has been an upsurge in the number of clinical trials involving chemically modified
oligonucleotide-based drug candidates after the FDA approval of Vitravene, Macugen, and …

RNA plays a central role in the expression of all genes. Because any sequence within RNA
can be recognized by complementary base pairing, synthetic oligonucleotides and …

This unit presents an update of recent developments and clinical progress in chemically
modified oliogonucleotides useful for therapeutic applications. During the last decade, the …

Oligonucleotide therapeutics have the potential to become a third pillar of drug development
after small molecules and protein therapeutics. However, the three approved …

Chemically modified antisense oligonucleotides are currently progressing in multiple clinical
trials. Among several chemical modifications made, modification of the 2'-position has …

Among the multitude of chemical modifications that have been described over the past two
decades, oligonucleotide analogs that are modified at the 2′‐position of the furanose sugar …

Oligonucleotides (ONs) can interfere with biomolecules representing the entire extended
central dogma. Antisense gapmer, steric block, splice-switching ONs, and short interfering …

Under clinical development since the early 90's and with two successfully approved drugs
(Fomivirsen and Mipomersen), oligonucleotide-based therapeutics has not yet delivered a …

Numerous chemically modified oligonucleotides have been developed so far and show their
own unique chemical properties and pharmacodynamic/pharmacokinetic characteristics …

The use of antisense oligonucleotides as therapeutic agents has generated considerable
enthusiasm in the research and medical community. Antisense oligonucleotides as …